DB Schenker and Cargolux will launch a full charter cargo connection between Luxembourg and Indianapolis, USA, starting January 2021.

With weekly departures on a Boeing 747 freighter, DB Schenker makes Cargolux’s extensive experience in the handling of pharmaceutical and healthcare goods available for its customers in Europe and Northern America along with creating capacities for potential COVID-19 vaccine transportation demand.

By partnering with the airline that was the first to be GDP certified, back in 2014, DB Schenker reaches a milestone in setting up its new healthcare service portfolio DB SCHENKERlife+. With pharma handling expertise throughout its network and a dedicated Healthcare Centre in Luxembourg, Cargolux is the ideal partner for DB SCHENKERlife+ which has patient safety, quality and reliability in its DNA.

With this new agreement both partners look to expand their well-established 15 year-long partnership. Cargolux’s initial service between its home base in Luxembourg and the Indiana capital was inaugurated in 2005 to support DB Schenker’s business in the region. The successful collaboration has grown over the years and is now cemented through this charter solution.

Veronique Dameme, Head of Global Vertical Market Healthcare at DB Schenker said, “Our new product portfolio DB SCHENKERlife+ offers exceptional quality, unconditional security and fully reliable logistics services. The cooperation with Cargolux expands the foundation for our robust global GDP program and customised services as Air Track, 24/7 monitoring, packaging supplies or telemetric devices. In such volatile times DB SCHENKERlife+ thus provides urgently needed transparency and predictability.”

Domenico Ceci, Cargolux’s Executive Vice- President Sales & Marketing said, “Cargolux is pleased to launch this new weekly charter service in collaboration with DB Schenker. Both companies have enjoyed a fruitful and mutually beneficial partnership on this lane over the past 15 years and we are happy to expand on this success.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here